- References (1)
- Inventor Info
|Parental Line||3LL aka LL/2 (LLC1) likely origin - please note genetic divergence in relevance information|
|Relevance||Murine Lewis Lung Adenocarcinoma engineered cell line with NRAS knocked out using CRISPR-Cas9. Please note: The authors have established (by DNA sequencing) that these cells are homozygous for the KRAS-G12C & NRAS-Q61H mutations which is not the case for the parent 3LL ATCC line. It is assumed both mutant NRAS and KRAS in 3LL cells drive RAS pathway activation. By knocking out NRAS a tumourigenic cell line with a stronger dependency on KRAS-G12C was generated. Model cell line for study of the effect of KRAS-G12C inhibitors on oncogenic cells.|
|Research Area||Cancer, Cell Cycle, Cell Signaling & Signal Transduction|
|Recommended Growing Conditions||RPMI+10%FCS+1%PS|
CRISPR edited 3LL cells.
Cancer Research Technology Limited (trading research tools as Ximbio) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed here.
This license from ERS Genomics Ltd allows Ximbio to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. Ximbio can provide these modified CRISPR-Cas9 cell lines to companies under a label-use only license.
There are 1 reference entries for this reagent.View All References
Add an inventor